Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

10,000 New Ebola Cases Per Week Could Be Seen

October 14, 2014 11:26 am | by Maria Cheng, AP Medical Writer - Associated Press | News | Comments

West Africa could see up to 10,000 new Ebola cases a week within two months, the World Health Organization said, also confirming the death rate in the current outbreak has risen to 70%. Read more...                                      

TOPICS:

C3BS Enrolls Patients in Switzerland in its Phase 3 Clinical Trial Chart-1

October 14, 2014 10:39 am | News | Comments

C3BS, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announced it has received authorization from Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase 3 trial for C-Cure in Switzerland. Read more...

TOPICS:

Chemical Derived from Broccoli Sprouts Shows Promise in Treating Autism

October 14, 2014 10:27 am | News | Comments

Results of a small clinical trial suggest that a chemical derived from broccoli sprouts — and best known for claims that it can help prevent certain cancers — may ease classic behavioral symptoms in those with autism spectrum disorders (ASDs). Read more...

TOPICS:
Advertisement

Researchers Treat Pulmonary Hypertension Through the Leaves of Plants

October 14, 2014 10:18 am | News | Comments

Researchers at the University of Pennsylvania and the University of Florida have identified a drug that can be used to treat pulmonary hypertension, a disease for which few therapy options exist. Read more...                            

TOPICS:

Scientists Link ALS Progression to Increased Protein Instability

October 14, 2014 10:09 am | News | Comments

A new study by scientists from The Scripps Research Institute (TSRI), Lawrence Berkeley National Laboratory (Berkeley Lab) and other institutions suggests a cause of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. Read more...

TOPICS:

Canadian Ebola Vaccine Begins Testing

October 14, 2014 10:00 am | News | Comments

Human testing of an experimental Canadian-made Ebola vaccine began, with federal officials saying the drug could be shipped to West Africa within months if it proves successful. Read more...

TOPICS:

Targeted Payload Therapies Using RIT Hit the Right Marks

October 13, 2014 4:50 pm | by Dragan Cicic, M.D., MBA, Chief Operating Officer and Chief Medical Officer, Actinium Pharmaceuticals | Articles | Comments

For patients with acute myeloid leukemia (AML), there is both good news and bad news – the good news is that standard induction therapy, using cytarabine and an anthracycline, produces complete responses in half to almost three-quarters of cases. The bad news? Read more...

TOPICS:

New Cancer Drug to Begin Trials in Multiple Myeloma Patients

October 13, 2014 3:11 pm | News | Comments

Scientists at Imperial College London have developed a new cancer drug which they plan to trial in multiple myeloma patients by the end of next year. Read more...                            

TOPICS:
Advertisement

Greater Rates of Mitochondrial Mutations in Children Born to Older Mothers

October 13, 2014 2:54 pm | News | Comments

The discovery of a "maternal age effect" by a team of Penn State scientists that could be used to predict the accumulation of mitochondrial DNA mutations in maternal egg cells -- and the transmission of these mutations to children -- could provide valuable insights for genetic counseling. Read more... 

TOPICS:

Nuvilex Applies for Orphan Drug Designation for Pancreatic Cancer Treatment

October 13, 2014 2:43 pm | News | Comments

Nuvilex Inc. (NVLX), a clinical-stage biotechnology company developing cell therapy solutions for the treatment of diseases, announced that it has submitted an application to the FDA for Orphan Drug Designation for its Cell-in-a-Box(R) treatment for pancreatic cancer. Read more...

TOPICS:

Pfizer Gets FDA Acceptance of Palbociclib

October 13, 2014 2:35 pm | News | Comments

Pfizer Inc. announced the New Drug Application (NDA) for palbociclib has been accepted for filing and granted Priority Review by the United States Food and Drug Administration (FDA). Read more...                                

TOPICS:

BMS, Pharmacyclics and Janssen Collaborate on Non-Hodgkin Lymphoma Drug

October 13, 2014 2:25 pm | News | Comments

Bristol-Myers Squibb Company, Pharmacyclics Inc., and Janssen Research & Development LLC announced they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) in combination with Imbruvica. Read more...

TOPICS:

CDC Urges All U.S. Hospitals to Think 'Ebola'

October 13, 2014 2:13 pm | by Connie Cass | News | Comments

The government is telling the nation's hospitals to "think Ebola." Every hospital must know how to diagnose Ebola in people who have been in West Africa and be ready to isolate a suspected case, Tom Frieden, director of the Centers for Disease Control and Prevention, said. Read more...

TOPICS:

Scientists Characterize a New Tumor Syndrome

October 13, 2014 11:08 am | News | Comments

Scientists at the Luxembourg Center for Systems Biomedicine (LCSB) of the University of Luxembourg have published their findings that mutations in a gene known as “ARMC5” promote the growth of benign tumors in the adrenal glands and on the meninges: ARMC5 appears to belong to the group of so-called tumour suppressor gene. Read more...

TOPICS:

Concert Pharmaceuticals' Spasticity Drug Gets Positive Reviews

October 13, 2014 10:54 am | News | Comments

Concert Pharmaceuticals Inc. announced Phase 1 data of CTP-354, a novel, potentially first-in-class, non-sedating, once-daily oral treatment for spasticity. Read more...                        

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading